Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor

Grabar, Sophie, Pradier, Christian, Le Corfec, Emmanuelle, Lancar, Rémi, Allavena, Clotilde, Bentata, Michelle, Berlureau, Patricia, Dupont, Caroline, Fabbro-Peray, Pascale, Poizot-Martin, Isabelle, Costagliola, Dominique · 2000 · AIDS

Abstract

OBJECTIVE: To determine the predictors of virological and clinical failure in patients receiving a protease inhibitor as part of triple therapy. METHODS: From the French Hospital Database on HIV, 1402 protease inhibitor-naive patients starting a highly active antiretroviral therapy regimen with ritonavir, saquinavir-hard gel capsule (hgc) or indinavir between July 1996 and March 1997, and with measured HIV RNA at baseline and at 12 months, were studied for progression to a new AIDS-defining event (ADE) or death. Virological failure was defined as plasma HIV RNA > 1000 copies/ml at 12 months. Multivariate analyses were performed using Cox models for clinical outcomes and logistic regression for virological outcomes. RESULTS: During a median follow-up of 14.1 months, 94 (6.7%) patients experienced an ADE or died. At 12 months, 700 patients (49.9%) had virological failure. In the multivariate analysis, baseline CD4 cell count and viral load were found to be independent predictors of both virological and clinical failure. Neither the type of the first protease inhibitor taken nor previous antiretroviral therapy experience was associated with risk of clinical progression. For virological failure, the use of saquinavir-hgc was associated with a significant 1.96-fold increase in risk compared with indinavir; pre-treated patients were at higher risk than antiretroviral therapy-naive patients. CONCLUSION: In this study with large samples of patients, the use of saquinavir-hgc was associated with higher risk of virological failure at 12 months than were ritonavir and indinavir; no differences between protease inhibitors were found for clinical progression. As biases cannot be excluded, a longer duration of follow-up will be necessary to answer the question of whether the results are really discrepant or simply reflect the delay between virological failure and clinical manifestations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002030-200001280-00009

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 175

Metadata

Authors
Grabar, S., Pradier, C., Le Corfec, E., Lancar, R., Allavena, C., Bentata, M., Berlureau, P., Dupont, C., Fabbro-Peray, P., Poizot-Martin, I., & Costagliola, D.
Venue
AIDS
Published
2000-01
Volume
14
Issue
2
Pages
141-149
ISSN
0269-9370 (ISSN-L)
OpenAlex
W1990161832
Cited by
175
References
1
FWCI
14.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. https://app.cochat.ai/papers/10.1097/00002030-200001280-00009
The paper
Grabar, S., Pradier, C., Le Corfec, E., Lancar, R., Allavena, C., Bentata, M., Berlureau, P., Dupont, C., Fabbro-Peray, P., Poizot-Martin, I., & Costagliola, D. (2000). Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. https://doi.org/10.1097/00002030-200001280-00009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.